Grufity logoGrufity logo
ScreenerStocksFundsSectorsWatchlists
REPL

Replimune Group Inc

REPL

7.33USD+0.58 (+8.59%)Market Closed
Watchlist

Market Summary

USD7.33+0.58
Market Closed
8.59%

REPL Stock Price

View Fullscreen

REPL RSI Chart

REPL Valuation

Market Cap

432.9M

Price/Earnings (Trailing)

-2.18

Price/Sales (Trailing)

20.56

EV/EBITDA

-3.13

Price/Free Cashflow

-2.79

REPL Price/Sales (Trailing)

REPL Profitability

EBT Margin

-1738.92%

Return on Equity

-31.39%

Return on Assets

-26.96%

Free Cashflow Yield

-35.85%

REPL Fundamentals

REPL Revenue

Revenue (TTM)

21.1M

Revenue Y/Y

953.83%

Revenue Q/Q

-2.21%

REPL Earnings

Earnings (TTM)

-198.6M

Earnings Y/Y

-39.31%

Earnings Q/Q

-21.06%

Price Action

Last 7 days

-35.2%

Last 30 days

-43.0%

Last 90 days

-62.6%

Trailing 12 Months

-61.2%

How does REPL drawdown profile look like?

REPL Financial Health

Current Ratio

17.52

Debt/Equity

0.05

Debt/Cashflow

-4.51

REPL Investor Care

Shares Dilution (1Y)

18.74%

Diluted EPS (TTM)

-3.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20239.7M15.6M21.1M0
20221.7M1.3M1.1M3.7M
20212.8M2.9M2.9M2.4M
20203.1M3.1M3.3M2.9M
20192.8M3.3M3.2M2.6M
20182.3M2.1M2.1M3.0M
20170000

Latest Insider Trading transactions for REPL

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 16, 2023
sarchi christopher
sold
-57,384
10.92
-5,255
chief commercial officer
Nov 16, 2023
xynos konstantinos
sold
-79,858
10.92
-7,313
chief medical officer
Sep 18, 2023
hill emily luisa
acquired
-
-
83,330
chief financial officer
Sep 12, 2023
esposito pamela
sold
-6,000
20.00
-300
chief business officer
Sep 12, 2023
esposito pamela
acquired
990
3.3
300
chief business officer
Sep 11, 2023
esposito pamela
acquired
17,681
3.3
5,358
chief business officer
Sep 11, 2023
esposito pamela
sold
-107,214
20.01
-5,358
chief business officer
Aug 22, 2023
esposito pamela
acquired
122,380
6.57957
18,600
chief business officer
Aug 22, 2023
esposito pamela
sold
-372,186
20.01
-18,600
chief business officer
Aug 11, 2023
esposito pamela
sold
-28,000
20.00
-1,400
chief business officer

1–10 of 50

Which funds bought or sold REPL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Nov 24, 2023
DEUTSCHE BANK AG\
reduced
-86.19
-2,824,680
320,094
-%
Nov 22, 2023
Graham Capital Management, L.P.
new
-
339,924
339,924
0.01%
Nov 21, 2023
Walleye Capital LLC
sold off
-100
-1,176,400
-
-%
Nov 15, 2023
MANUFACTURERS LIFE INSURANCE COMPANY, THE
added
13.88
-428,589
2,235,630
-%
Nov 15, 2023
Tudor Investment Corp Et Al
sold off
-100
-669,595
-
-%
Nov 15, 2023
MORGAN STANLEY
reduced
-28.18
-7,145,050
8,030,730
-%
Nov 15, 2023
JANE STREET GROUP, LLC
sold off
-100
-1,870,700
-
-%
Nov 15, 2023
CAPTRUST FINANCIAL ADVISORS
reduced
-3.4
-296,997
733,437
-%
Nov 14, 2023
Voya Investment Management LLC
added
1.75
-95,980
287,568
-%
Nov 14, 2023
TWO SIGMA INVESTMENTS, LP
sold off
-100
-4,228,620
-
-%

1–10 of 38

Latest Funds Activity

Are funds buying REPL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own REPL
No. of Funds

Schedule 13G FIlings of Replimune Group Inc

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
9.2%
5,064,744
SC 13G/A
Feb 14, 2023
redmile group, llc
9.9%
5,740,099
SC 13G/A
Feb 14, 2023
baker bros. advisors lp
9.99%
5,768,227
SC 13G
Feb 13, 2023
omega fund iv, l.p.
7.2%
3,610,478
SC 13G/A
Feb 03, 2023
blackrock inc.
5.5%
3,010,552
SC 13G
Nov 18, 2022
redmile group, llc
9.9%
5,165,131
SC 13G/A
Sep 14, 2022
atlas venture fund x, l.p.
4.4%
2,164,037
SC 13D/A
Feb 14, 2022
redmile group, llc
9.9%
4,775,461
SC 13G/A
Feb 14, 2022
omega fund iv, l.p.
10.6%
5,012,052
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
12.5%
5,868,638
SC 13G/A

Recent SEC filings of Replimune Group Inc

View All Filings
Date Filed Form Type Document
Dec 05, 2023
8-K
Current Report
Nov 17, 2023
4
Insider Trading
Nov 17, 2023
4
Insider Trading
Nov 07, 2023
8-K
Current Report
Nov 07, 2023
10-Q
Quarterly Report
Sep 20, 2023
4
Insider Trading
Sep 20, 2023
3
Insider Trading
Sep 19, 2023
8-K
Current Report
Sep 13, 2023
4
Insider Trading
Sep 07, 2023
8-K
Current Report

Peers (Alternatives to Replimune Group Inc)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
31.4B
-
4.92% 426363.59%
-3.6K
218.4K
- -102.45%
30.7B
10.7B
11.84% -53.56%
-8.86
2.88
-53.67% -129.46%
22.0B
1.7B
4.71% -20.32%
-43.06
12.74
79.37% 56.87%
17.7B
2.3B
23.54% -7.88%
120.62
7.68
15.05% 75.21%
12.4B
3.6B
1.56% -32.86%
29.22
3.44
8.35% -51.49%
MID-CAP
7.5B
272.9M
38.55% 34.32%
-12.3
27.31
141.38% 4.43%
5.6B
-
16.25% 246.63%
-9.66
48.33
54.84% -12.96%
3.5B
631.9M
-10.80% 43.56%
-23.57
5.55
23.54% 31.53%
3.3B
223.4M
11.07% -7.88%
-16.25
14.68
- -26.24%
2.6B
240.7M
-11.66% -25.68%
-12.44
10.6
-1.03% -16.59%
SMALL-CAP
1.5B
348.4M
7.85% -14.88%
24.07
4.29
81.69% -7.29%
662.5M
1.0B
-19.01% -66.75%
-1.21
0.63
-43.15% 58.48%
100.5M
6.4M
-2.56% -78.77%
-0.61
15.6
-44.11% 50.48%
42.3M
-
410.00% -4.38%
-0.65
-
- -29.23%
26.3M
-
17.86% 4717.52%
-0.55
-
- -13.74%

Replimune Group Inc News

Latest updates
InvestorIdeas.com06 Dec 202307:26 pm10 hours ago
Defense World06 Dec 202312:01 pm18 hours ago
Defense World06 Dec 202309:32 am20 hours ago
Defense World06 Dec 202306:25 am23 hours ago
Investing.com Türkiye06 Dec 202306:11 am24 hours ago
Investing.com México05 Dec 202309:35 pm32 hours ago
Investing.com05 Dec 202309:30 pm32 hours ago
英为财情 Investing.com05 Dec 202309:30 pm32 hours ago
Investing.com Polska05 Dec 202309:30 pm32 hours ago
Stocks Register05 Dec 202308:05 pm34 hours ago
Investing.com UK05 Dec 202307:27 pm34 hours ago
InvestorsObserver05 Dec 202307:18 pm34 hours ago
BioWorld Online05 Dec 202306:45 pm35 hours ago
Investing.com UK05 Dec 202306:06 pm36 hours ago

Financials for Replimune Group Inc

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue-2.2%6,049,0006,186,0006,145,0002,675,000574,000343,000131,00087,000725,000788,000816,000550,000755,000686,000859,000951,000620,000687,000325,5001,577,000664,000
Operating Expenses14.7%63,831,00055,648,00052,995,00041,630,00041,579,00040,876,00031,988,00029,698,00029,247,00027,381,00022,184,00020,275,00019,663,00017,833,00016,385,00016,664,00012,242,00010,907,0007,826,00010,137,0007,104,000
  S&GA Expenses-3.2%14,730,00015,211,00015,041,00011,369,00012,745,00011,398,00010,252,00010,345,0009,345,0008,827,0005,959,0005,953,0005,613,0005,676,0005,197,0004,716,0004,074,0003,450,0002,410,5002,280,0002,142,000
  R&D Expenses21.4%49,101,00040,437,00037,954,00030,261,00028,834,00029,478,00021,736,00019,353,00019,902,00018,554,00016,225,00014,322,00014,050,00012,157,00011,188,00011,948,0008,168,0007,457,0005,415,5007,857,0004,962,000
EBITDA Margin----16.95------------------
Interest Expenses-14.3%955,0001,115,0001,022,000941,000------1,000247,000286,000284,000-834,000195,000----
Income Taxes-200.0%-200,000200,000-----55,00012,000-------------
Earnings Before Taxes-22.1%-60,245,000-49,354,000---43,102,000-42,253,000---------------
EBT Margin----17.39------------------
Net Income-21.1%-60,044,000-49,600,000-49,238,000-39,690,000-43,102,000-42,300,000-31,696,000-29,674,000-29,355,000-27,311,000-21,499,000-21,783,000-20,095,000-17,493,000-15,789,000-16,189,000-11,139,000-9,508,000-6,656,000-7,673,000-6,461,000
Net Income Margin----17.42-37.05-25.61-41.13-37.22-35.22-34.72-31.17-28.81-27.59-22.26-20.64-17.06-15.24-----
Free Cashflow----33,047,000-29,144,000-33,606,000-34,523,000-23,709,000-18,813,000-23,389,000-18,605,000-16,898,000-13,607,000-17,254,000-16,022,000-12,600,000-19,791,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-6.9%562604647679436459461485503524543559314330234250151144154152154
  Current Assets-7.6%508550593624379402404428444465484499252268174191118128141145152
    Cash Equivalents-27.1%78.0010614720789.0011410813416219418432645.0010661.0063.0065.0040.0027.0022.0024.00
  Net PPE10.9%8.008.007.008.008.008.008.007.007.007.007.007.007.007.007.006.004.001.0012.006.000.00
Liabilities8.2%97.0090.0091.0083.0052.0049.0050.0048.0046.0045.0044.0043.0053.0052.0050.0053.0031.0013.0016.009.004.00
  Current Liabilities23.5%40.0032.0034.0026.0024.0020.0021.0018.0017.0015.0015.0013.0013.0012.0012.0014.0012.0013.0010.004.004.00
  Long Term Debt0.9%29.0029.0029.0028.00--------10.0010.0010.0010.0010.00----
    LT Debt, Non Current---29.00------------------
Shareholder's Equity-9.5%465514555595384410411438457479499516261278184198121130138143150
  Retained Earnings-11.2%-595-535-485-436-396-353-311-279-249-220-193-171-149-129-112-96.51-80.32-69.18-59.77-53.11-45.44
  Additional Paid-In Capital0.9%1,0551,0451,0351,028778763723717707700692688412409297295202200199198197
Shares Outstanding0.1%59.0059.0057.0057.0050.0054.0047.0052.0052.0052.0047.0049.0044.0040.0037.0033.0032.0032.0032.0032.0025.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations10.3%-43,590-48,588-32,796-28,589-33,210-33,455-22,557-18,348-22,961-18,314-16,128-12,992-17,179-15,090-11,262-15,735-19,973-13,582-6,033-6,103-6,383
  Share Based Compensation3.0%9,1158,8466,9227,0236,9927,1945,7735,9186,3136,2503,4723,0492,8012,4681,8062,3441,7811,810907880718
Cashflow From Investing72.3%12,6837,361-22,752-125,10136.005,315-4,326-13,420-11,05226,992-126,27331,421-44,798-49,1267,841-65,20925,32426,81110,4743,801-85,109
Cashflow From Financing-60.4%4381,105-77.00271,4357,42332,5223593,9691,1501,120785262,198-35.00109,51434.0090,3649,75018.0041.00153101,391

REPL Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:    
Research and development$ 49,101$ 28,834$ 89,538$ 58,312
Selling, general and administrative14,73012,74529,94124,143
Total operating expenses63,83141,579119,47982,455
Loss from operations(63,831)(41,579)(119,479)(82,455)
Other income (expense):    
Research and development incentives4435748361,425
Investment income6,0491,11212,2351,455
Interest expense on finance lease liability(542)(550)(1,086)(1,102)
Interest expense on debt obligations(955)0(2,070)0
Other (expense) income(1,409)(2,659)(35)(4,678)
Total other income (expense), net3,586(1,523)9,880(2,900)
Loss before income taxes(60,245)(43,102)(109,599)(85,355)
Income tax (benefit)(201)000
Net loss$ (60,044)$ (43,102)$ (109,599)$ (85,355)
Net loss per share attributable to common stockholders, basic (in dollars per share)$ (0.90)$ (0.79)$ (1.65)$ (1.57)
Net loss per share attributable to common stockholders, diluted (in dollars per share)$ (0.90)$ (0.79)$ (1.65)$ (1.57)
Weighted average common shares outstanding, basic (in shares)66,582,28054,770,29166,475,57754,492,395
Weighted average common shares outstanding, diluted (in shares)66,582,28054,770,29166,475,57754,492,395

REPL Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Mar. 31, 2023
Current assets:  
Cash and cash equivalents$ 75,996$ 146,590
Short-term investments420,765436,796
Research and development incentives receivable2,9002,939
Prepaid expenses and other current assets8,5146,278
Total current assets508,175592,603
Property, plant and equipment, net8,4457,479
Research and development incentives receivable, non-current8090
Restricted cash1,6361,636
Right-to-use asset - operating leases4,8825,208
Right-to-use asset - financing leases38,45139,665
Total assets562,398646,591
Current liabilities:  
Accounts payable4,3655,364
Accrued expenses and other current liabilities31,65124,704
Operating lease liabilities, current1,1381,118
Financing lease liabilities, current2,6782,639
Total current liabilities39,83233,825
Operating lease liabilities, non-current4,0524,389
Financing lease liabilities, non-current23,70923,965
Long term debt, net of discount29,16128,648
Other liabilities, non-current472472
Total liabilities97,22691,299
Commitments and contingencies (Note 14)
Stockholders' equity  
Common stock, $0.001 par value; 150,000,000 shares authorized as of September 30, 2023 and March 31, 2023; 59,059,343 and 56,676,313 shares issued and outstanding as of September 30, 2023 and March 31, 2023, respectively5957
Additional paid-in capital1,054,7121,034,994
Accumulated deficit(595,087)(485,488)
Accumulated other comprehensive income5,4885,729
Total stockholders' equity465,172555,292
Total liabilities and stockholders' equity$ 562,398$ 646,591
REPL
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
 CEO
 WEBSITEwww.replimune.com
 EMPLOYEES284

Replimune Group Inc Frequently Asked Questions


What is the ticker symbol for Replimune Group Inc? What does REPL stand for in stocks?

REPL is the stock ticker symbol of Replimune Group Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Replimune Group Inc (REPL)?

As of Wed Dec 06 2023, market cap of Replimune Group Inc is 432.9 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of REPL stock?

You can check REPL's fair value in chart. The fair value of Replimune Group Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Replimune Group Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for REPL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Replimune Group Inc a good stock to buy?

The fair value guage provides a quick view whether REPL is over valued or under valued. Whether Replimune Group Inc is cheap or expensive depends on the assumptions which impact Replimune Group Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for REPL.

What is Replimune Group Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 06 2023, REPL's PE ratio (Price to Earnings) is -2.18 and Price to Sales (PS) ratio is 20.56. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. REPL PE ratio will change depending on the future growth rate expectations of investors.